Long‐term impact of Elexacaftor/Tezacaftor/ivacaftor on pulmonary, nutritional and metabolic outcomes in homozygous F508del cystic fibrosis patients: A real‐world cohort study
A cohort study assesses long-term benefits of ETI on pulmonary, nutritional, and metabolic outcomes in cystic fibrosis patients, indicating multidisciplinary monitoring is essential.
Key Points
This research evaluates the long-term effects of Elexacaftor/Tezacaftor/Ivacaftor on various health parameters in cystic fibrosis patients.
Retrospective analysis of 112 cystic fibrosis patients
Data collected at baseline, 6, 12, 24, and 30 months
Assessment of clinical, spirometric, and biochemical data
Sustained lung function gains (+15 FEV₁ points at 24 months)
Increase in BMI (+1.7 kg/m² in year one)
Reduction in C-reactive protein (−80% at 6 months)
Decrease in pulmonary exacerbations (85%)
Nutritional improvements with decreased underweight prevalence from 12.5% to 1.8%